Subscribe or Manage Preferences
VBCR - June 2016, Vol 5, No 3 - Rheumatology Update
E. K. Charles

Providing treatment options for patients with rheumatoid arthritis is paramount to treating the disease. Although existing therapies have been effective, treatment response is still a concern in this patient population.

“Biologic drug therapies represent a huge advance in treatment of rheumatoid arthritis,” Darren Plant, PhD, National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, United Kingdom, and colleagues explained. “How­ever, very good disease control is achieved in only 30% of patients, making identification of biomarkers of response a research priority.”

Allele Linked to Nonresponse

To determine whether differential DNA methylation patterns are a useful biomarker of tumor necrosis factor inhibitor therapy response, the investigators conducted an epigenome-wide association study to look at differences between good responders and nonresponders treated with etanercept. The data used for this study were based on patients from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, and included patients aged ≥18 years who were clinically classified with rheumatoid arthritis per the American College of Rheumatology criteria. Thirty-six patients were included in each group, and response at 3 months was the time frame of interest.

Altogether, 5 positions were differently methylated between responders and nonresponders; the top 2 positions mapped to exon 7 of the LRPAP1 gene on chromosome 4. In addition, Dr Plant and colleagues identified a correlation between the A allele of the single-nucleotide polymorphism rs3468 and higher levels of methylation for these 2 positions. That particular allele was also associated with nonresponse, based on criteria from the European League Against Rheumatism.

Treatment Response Multifactorial

These data point to the functional significance of the LRPAP1 gene. The gene itself is highly expressed in mononuclear blood cells, and encodes a protein that influences transforming growth factor β activity. Targeted ribonucleic acid sequencing of specific cell types in whole blood should be considered in future research, the study authors noted.

Although treatment response is multifactorial, Dr Plant and colleagues concluded, biomarker panels that include serology, and epigenetic, genetic, and transcriptomic factors may help better predict treatment response to therapy in patients with rheumatoid arthritis.




Reference

  1. Plant D, Webster A, Nair N, et al. Differential methylation as a biomarker of response to etanercept in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1353-1360.
Related Items
Preparing for the Shortage of Rheumatologists Projected for 2030
Alice Goodman
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Rheumatology Update
Latest Data from the CDC Suggest That 1 in 4 US Adults Are Diagnosed with Arthritis
Sophie Granger
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Rheumatology Update
Young Patients with Glenohumeral Arthritis: Etiology, Diagnosis, and Treatment
E. K. Charles
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Arthritis
Tug-of-War Between Ideal Lifestyle Habits and Reality Observed in Patients with RA
E. K. Charles
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Health & Wellness
May Is National Arthritis Awareness Month
Sophie Granger
VBCR - April 2016, Vol 5, No 2 published on May 9, 2016 in Rheumatology Update
Higher Cost-Sharing Associated with Reductions in Utilization of Specialty Drugs
E. K. Charles
VBCR - April 2016, Vol 5, No 2 published on May 6, 2016 in Rheumatology Update
Fracture of Proximal Bones Often Harbinger of Premature Death
Phoebe Starr
VBCR - April 2016, Vol 5, No 2 published on May 5, 2016 in Rheumatology Update
Ultrasound Not Necessary in T2T Strategy
Phoebe Starr
VBCR - April 2016, Vol 5, No 2 published on May 3, 2016 in Rheumatology Update
Smoking Stronger Risk Factor for Interstitial Lung Disease in Patients with RA Than in Healthy People
E. K. Charles
VBCR - April 2016, Vol 5, No 2 published on May 2, 2016 in Rheumatoid Arthritis
Better Disease Control Needed in Patients with Gout
E. K. Charles
VBCR - April 2016, Vol 5, No 2 published on April 29, 2016 in Gout
Last modified: July 12, 2016
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology